• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Astrana Health Inc.

    4/25/25 4:16:36 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary
    Get the next $ASTH alert in real time by email
    DEFA14A 1 tm252605d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material Pursuant to §240.14a-12

     

    Astrana Health, Inc.

     

     

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required.
    ¨Fee paid previously with preliminary materials.
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V70197-P32019 ASTRANA HEALTH, INC. 1668 S. GARFIELD AVENUE 2ND FLOOR ALHAMBRA, CA 91801 ASTRANA HEALTH, INC. 2025 Annual Meeting Vote by June 10, 2025 11:59 PM ET Vote in Person at the Meeting* June 11, 2025 10:00 AM PT 1668 S. Garfield Avenue 3rd Floor Conference Room Alhambra, CA 91801 You invested in ASTRANA HEALTH, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 11, 2025. Get informed before you vote View the Notice of Annual Meeting, Proxy Statement, and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V70198-P32019 Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect nine directors to the Board of Directors, each to hold office until the 2026 annual meeting of stockholders of the Company. For Nominees: 01) Kenneth Sim, M.D. 02) Thomas S. Lam, M.D., M.P.H. 03) Mitchell W. Kitayama 04) David G. Schmidt 05) Linda Marsh 06) John Chiang 07) Matthew Mazdyasni 08) J. Lorraine Estradas, R.N., B.S.N., M.P.H. 09) Weili Dai 2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. To approve, on a non-binding advisory basis, the compensation program for the Company’s named executive officers as disclosed in the Company’s proxy statement. For 4. To approve the Astrana Health, Inc. Amended and Restated 2024 Equity Incentive Plan. For NOTE: In their discretion, the proxies are authorized to vote on any such other business that may properly be presented before the annual meeting or at any adjournment or postponement thereof.

     

    Get the next $ASTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTH

    DatePrice TargetRatingAnalyst
    12/12/2025$28.00Buy
    Needham
    4/1/2025$36.00Equal Weight
    Barclays
    10/14/2024$66.00Buy
    TD Cowen
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    7/11/2024$44.00 → $50.00Hold → Buy
    Truist
    5/30/2024$54.00Outperform
    Robert W. Baird
    More analyst ratings

    $ASTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Astrana Health Inc.

    SCHEDULE 13G/A - Astrana Health, Inc. (0001083446) (Subject)

    1/30/26 1:26:26 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Astrana Health, Inc. (0001083446) (Filer)

    1/12/26 4:06:05 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    SEC Form D filed by Astrana Health Inc.

    D - Astrana Health, Inc. (0001083446) (Filer)

    11/21/25 4:15:27 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call

    ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.

    1/26/26 8:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. to Participate in Upcoming Investor Conference

    ALHAMBRA, Calif., Jan. 6, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership is participating in the J.P. Morgan 2026 Healthcare Conference, being held in San Francisco, on Monday, January 12, 2026, including a presentation at 5:15pm PT. The webcast link and related presentation materials will be available in the "IR Calendar" section of the Company's website: https://ir.astranahealth.com/news-events/ir-calendar.

    1/6/26 8:07:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Reports Third Quarter 2025 Results

    Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (

    11/6/25 4:05:00 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Astrana Health with a new price target

    Needham initiated coverage of Astrana Health with a rating of Buy and set a new price target of $28.00

    12/12/25 8:48:58 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Barclays initiated coverage on Astrana Health with a new price target

    Barclays initiated coverage of Astrana Health with a rating of Equal Weight and set a new price target of $36.00

    4/1/25 7:41:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    TD Cowen initiated coverage on Astrana Health with a new price target

    TD Cowen initiated coverage of Astrana Health with a rating of Buy and set a new price target of $66.00

    10/14/24 7:24:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Sim Brandon exercised 21,334 shares at a strike of $23.24, increasing direct ownership by 2% to 1,045,329 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    2/3/26 9:37:01 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Chief Medical Officer Kumar Dinesh M. covered exercise/tax liability with 10,759 shares, decreasing direct ownership by 5% to 202,032 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    1/27/26 5:01:15 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Director Schmidt David exercised 20,000 shares at a strike of $5.79 and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 100% to 31,494 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    1/15/26 4:15:11 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Financials

    Live finance-specific insights

    View All

    Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call

    ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.

    1/26/26 8:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Reports Third Quarter 2025 Results

    Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (

    11/6/25 4:05:00 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Schedules 2025 Third Quarter Financial Results Release and Conference Call

    ALHAMBRA, Calif., Oct. 15, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the third quarter ended September 30, 2025, after the close of the stock market on Thursday, November 6, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

    10/15/25 9:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary